Incretin Mimetics
Diabetes Drugs and Pancreatic Cancer
If you or a loved one was prescribed incretin-based therapy for treatment of diabetes and was diagnosed with pancreatic cancer, you may be entitled to compensation.
Incretin Mimetics
In healthy individuals, eating triggers the production of incretin hormones such as glucagon like peptide-1 (GLP-1).
Incretin hormones:
- Release insulin, which lowers blood sugar
- Slow gastric emptying, so you stay full longer
- Slow the release of glucagon, which is sugar stored in the liver, so blood sugar stays at a healthy level
In Type 2 diabetes, the production of incretin hormones can be deficient. A class of drugs known as “incretin mimetics†or “GLP-1 agonists†imitate the incretin hormones, helping a person with Type 2 diabetes regulate their blood sugar.
Increase risk of pancreatic cancer
Unfortunately, recent studies at UCLA and a review of adverse event reports to the FDA have shown that incretin mimetics are associated with a significant increase in pancreatic cancer.
Brand names include:
- Bydurone
- Byetta
- Januvia
- Javumet
- Onglyza
- Victoza
We are here to help
If you or someone you care about was prescribed a drug for the treatment of Type 2 diabetes and was diagnosed with pancreatic cancer, contact Brown and Crouppen today for a free and confidential case evaluation.
We can help you make informed decisions about your legal rights, so please call us toll-free: 800-536-4357 for your free legal consultation or save time with our online contact form.
